Protagonist Therapeutics (PTGX) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• Protagonist Therapeutics is set to announce its Q2 2025 earnings on August 5th, with analysts estimating a loss of ($0.53) per share and revenue of $8.32 million.
• The company reported a previous quarter loss of ($0.19) per share, surpassing expectations, and had revenue of $28.32 million compared to a forecast of $30.44 million.
• Various analysts have issued ratings ranging from "buy" to "hold," with the average target price for the stock standing at $66.10.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 5th. Analysts expect Protagonist Therapeutics to post earnings of ($0.53) per share and revenue of $8.32 million for the quarter.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.31. The firm had revenue of $28.32 million during the quarter, compared to the consensus estimate of $30.44 million. Protagonist Therapeutics had a return on equity of 9.22% and a net margin of 27.04%. On average, analysts expect Protagonist Therapeutics to post $2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Protagonist Therapeutics Stock Performance

PTGX traded down $0.39 during trading on Wednesday, hitting $54.62. The stock had a trading volume of 388,819 shares, compared to its average volume of 666,291. The firm has a market capitalization of $3.39 billion, a P/E ratio of 72.83 and a beta of 2.26. Protagonist Therapeutics has a twelve month low of $32.50 and a twelve month high of $60.60. The company's 50-day moving average price is $52.87 and its 200 day moving average price is $46.52.

Insider Transactions at Protagonist Therapeutics

In related news, insider Arturo Md Molina sold 10,000 shares of the stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $57.03, for a total transaction of $570,300.00. Following the transaction, the insider directly owned 83,892 shares in the company, valued at approximately $4,784,360.76. This represents a 10.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Dinesh V. Ph D. Patel sold 10,415 shares of Protagonist Therapeutics stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $54.78, for a total value of $570,533.70. Following the completion of the sale, the chief executive officer owned 520,603 shares of the company's stock, valued at $28,518,632.34. This trade represents a 1.96% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 72,859 shares of company stock valued at $4,020,877. Insiders own 4.90% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Millennium Management LLC raised its holdings in Protagonist Therapeutics by 283.6% in the first quarter. Millennium Management LLC now owns 134,269 shares of the company's stock valued at $6,493,000 after buying an additional 99,269 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Protagonist Therapeutics by 0.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,403 shares of the company's stock worth $1,810,000 after acquiring an additional 348 shares in the last quarter. Finally, Royal Bank of Canada boosted its holdings in Protagonist Therapeutics by 30.6% in the 1st quarter. Royal Bank of Canada now owns 9,964 shares of the company's stock worth $482,000 after acquiring an additional 2,334 shares during the period. 98.63% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on PTGX. Citigroup initiated coverage on Protagonist Therapeutics in a report on Tuesday, June 17th. They issued a "buy" rating and a $72.00 price objective on the stock. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price target on shares of Protagonist Therapeutics in a research note on Tuesday, June 3rd. Finally, Wall Street Zen upgraded Protagonist Therapeutics from a "sell" rating to a "hold" rating in a research report on Sunday, June 8th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Protagonist Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $66.10.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.